Jeanne Dekdebrun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeanne Dekdebrun has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Charles A. Thornton
Department of Neurology
2 shared publications Aileen Jones
Center for Inherited Myology Research and
1 shared publication- Alison Gaynor
Center for Inherited Myology Research and
1 shared publication - Amanda Butler
Center for Inherited Myology Research and
1 shared publication - Araya Puwanant
The University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
1 shared publication - Barbara G. Vickrey
Department of Neurology, University of California, Los Angeles, CA 90095-1769, USA; VA Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
1 shared publication
Latest Publications
- Open Access
- 31 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1
BACKGROUND: Myotonic dystrophy type 1 (DM1) is a multisystemic, CTG repeat expansion disorder characterized by a slow, progressive decline in skeletal muscle function. A biomarker correlating RNA mis-splicing, the core pathogenic disease mechanism, and muscle performance is crucial for assessing response to disease-modifying interventions. We evaluated the Myotonic Dystrophy Splice Index (SI), a composite RNA splicing biomarker incorporating 22 disease-specific events, as a potential biomarker of DM1 muscle weakness. METHODS: Total RNA sequencing of tibialis anterior biopsies from 58 DM1 participants and 33 unaffected/disease controls was used to evaluate RNA splicing events across the disease spectrum. Targeted RNA sequencing was used to derive the SI from biopsies collected at baseline ( n = 52) or a 3-month ( n = 37) follow-up visit along with clinical measures of muscle performance. RESULTS: The SI demonstrated significant associations with measures of muscle strength and ambulation, including ankle dorsiflexion (ADF) strength and 10-meter run/fast walk (Pearson’s r = –0.719 and –0.680, respectively). The SI was relatively stable over 3 months (intraclass correlation coefficient [ICC] = 0.863). Latent-class analysis identified 3 DM1 subgroups stratified by baseline SI (SI Mild , SI Moderate , and SI Severe ); SI Moderate individuals had a significant increase in the SI over 3 months. Multiple linear regression modeling revealed that baseline ADF and SI were predictive of strength at 3 months (adjusted R ² = 0.830). CONCLUSION: The SI is a reliable biomarker that captures associations of RNA mis-splicing with physical strength and mobility and has prognostic utility to predict future function, establishing it as a potential biomarker for assessment of therapeutic target engagement. TRIAL REGISTRATION: ClinicalTrials.gov NCT03981575. FUNDING: FDA (7R01FD006071), Myotonic Dystrophy Foundation, Wyck Foundation, Muscular Dystrophy Association, Novartis, Dyne, Avidity, PepGen, Takeda, Sanofi Genzyme, Pfizer, Arthex, and Vertex Pharmaceuticals.
- 31 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (4)
Open AccessThe Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1
BACKGROUND: Myotonic dystrophy type 1 (DM1) is a multisystemic, CTG repeat expansion disorder characterized by a slow, progressive decline in skeletal muscle function. A biomarker correlating RNA mis-splicing, the core pathogenic disease mechanism, and muscle performance is crucial for assessing response to disease-modifying interventions. We evaluated the Myotonic Dystrophy Splice Index (SI), a composite RNA splicing biomarker incorporating 22 disease-specific events, as a potential biomarker of DM1 muscle weakness. METHODS: Total RNA sequencing of tibialis anterior biopsies from 58 DM1 participants and 33 unaffected/disease controls was used to evaluate RNA splicing events across the disease spectrum. Targeted RNA sequencing was used to derive the SI from biopsies collected at baseline ( n = 52) or a 3-month ( n = 37) follow-up visit along with clinical measures of muscle performance. RESULTS: The SI demonstrated significant associations with measures of muscle strength and ambulation, including ankle dorsiflexion (ADF) strength and 10-meter run/fast walk (Pearson’s r = –0.719 and –0.680, respectively). The SI was relatively stable over 3 months (intraclass correlation coefficient [ICC] = 0.863). Latent-class analysis identified 3 DM1 subgroups stratified by baseline SI (SI Mild , SI Moderate , and SI Severe ); SI Moderate individuals had a significant increase in the SI over 3 months. Multiple linear regression modeling revealed that baseline ADF and SI were predictive of strength at 3 months (adjusted R ² = 0.830). CONCLUSION: The SI is a reliable biomarker that captures associations of RNA mis-splicing with physical strength and mobility and has prognostic utility to predict future function, establishing it as a potential biomarker for assessment of therapeutic target engagement. TRIAL REGISTRATION: ClinicalTrials.gov NCT03981575. FUNDING: FDA (7R01FD006071), Myotonic Dystrophy Foundation, Wyck Foundation, Muscular Dystrophy Association, Novartis, Dyne, Avidity, PepGen, Takeda, Sanofi Genzyme, Pfizer, Arthex, and Vertex Pharmaceuticals.
- 4 June 2015
- Published by Wiley in Muscle & Nerve
- Vol. 53 (2) , 183-190
Myotonic dystrophy health index: Correlations with clinical tests and patient function
Introduction: The Myotonic Dystrophy Health Index (MDHI) is a disease‐specific patient‐reported outcome measure. Here, we examine the associations between the MDHI and other measures of disease burden in a cohort of individuals with myotonic dystrophy type‐1 (DM1). Methods: We conducted a cross‐sectional study of 70 patients with DM1. We examined the associations between MDHI total and subscale scores and scores from other clinical tests. Participants completed assessments of strength, myotonia, motor and respiratory function, ambulation, and body composition. Participants also provided blood samples, underwent physician evaluations, and completed other patient‐reported outcome measures. Results: MDHI total and subscale scores were strongly associated with muscle strength, myotonia, motor function, and other clinical measures. Conclusions: Patient‐reported health status, as measured by the MDHI, is associated with alternative measures of clinical health. These results support the use of the MDHI as a valid tool to measure disease burden in DM1 patients. Muscle Nerve, 2015 Muscle Nerve 53: 183–190, 2016
- 4 June 2015
- Published by Wiley in Muscle & Nerve
- Vol. 53 (2) , 183-190
Myotonic dystrophy health index: Correlations with clinical tests and patient function
Introduction: The Myotonic Dystrophy Health Index (MDHI) is a disease‐specific patient‐reported outcome measure. Here, we examine the associations between the MDHI and other measures of disease burden in a cohort of individuals with myotonic dystrophy type‐1 (DM1). Methods: We conducted a cross‐sectional study of 70 patients with DM1. We examined the associations between MDHI total and subscale scores and scores from other clinical tests. Participants completed assessments of strength, myotonia, motor and respiratory function, ambulation, and body composition. Participants also provided blood samples, underwent physician evaluations, and completed other patient‐reported outcome measures. Results: MDHI total and subscale scores were strongly associated with muscle strength, myotonia, motor function, and other clinical measures. Conclusions: Patient‐reported health status, as measured by the MDHI, is associated with alternative measures of clinical health. These results support the use of the MDHI as a valid tool to measure disease burden in DM1 patients. Muscle Nerve, 2015 Muscle Nerve 53: 183–190, 2016